本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Nov. 7, 2024 /PRNewswire/ -- On November 5, the 7th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center in Shanghai. As a seven-time attendee of the CIIE, Fosun showcased the latest achievements in innovation and global operations at its Fosun Pharma booth in Hall 7.1, featuring cutting-edge medical devices and innovative pharmaceuticals that made their debut in China. Guo Guangchang, Chairman of Fosun International, remarked, "Over the past seven years, CIIE has improved every year, becoming a window for China to build a new development framework, a platform for high-level openness, and an international public product for global sharing. Fosun has been a participant, witness, and beneficiary of the CIIE. Leveraging the CIIE platform, our long-term innovations have continually been put into practice, transforming many 'exhibits' into 'products', and converting many overseas partners from 'exhibitors' into 'investors'. This year, we continue to showcase our latest achievements in integrated innovation in the medical device and health sector, including several 'world's firsts' and 'China's firsts'. We firmly believe that China remains a significant opportunity for global development. Together with more overseas companies and global partners, we will promote more cutting-edge innovations to take root in China, moving forward and achieving mutual success on the grand stage of the CIIE." Stars of CIIE Taking Root, Transforming Ion from "Exhibit" to "Product" Healthcare is one of Fosun's main businesses. With CIIE's "spillover effect," several star products from Fosun, supported by the CIIE "accelerator" effect, have successfully entered the market to serve Chinese patients, transforming from "exhibits" into "products". This year, following the popular da Vinci Surgical System, the Ion Robotic Bronchoscopy made its CIIE debut after receiving domestic approval. Since its first appearance at the CIIE in 2019, Ion caught the attention of visitors. By the end of 2022, Ion entered the National Medical Products Administration's 'Green Channel' for innovative products and gained approval in March 2024, with the first commercial application completed in September. Lung cancer is considered the leading cause of cancer deaths, with 1.06 million new cases in China in 2022. The five-year survival rate is only 19.7%, and bronchoscopy is a key diagnostic tool for early lung cancer detection. The Ion bronchoscopy navigation control system offers innovative features for precise, convenient clinical diagnosis, providing new options for patients. By the third quarter of this year, 736 Ion systems had been installed globally, with over 150,000 Ion procedures performed. Outside the CIIE exhibition hall, Fosun is accelerating the localization of advanced medical devices. In June this year, Intuitive Fosun's headquarter industrial base was launched in Shanghai, marking Intuitive's largest R&D, production, and training center in the Asia-Pacific region. At this base, in addition to the Ion shape-sensing bronchoscopy control system, advanced products and core components, including the da Vinci surgical robot, are gradually achieving "Made in China, joint R&D, and global sales." Accelerating Integrated Innovation to Lead in Neurological Disease Treatment Transformation Fosun has long committed to investing in cutting-edge areas of healthcare, fostering a continuous stream of breakthrough "solid achievements" through an open innovation ecosystem involving independent R&D, collaborative development, licensing, and industry investment. These innovations are continually transformed into new drivers of growth. At this year's CIIE, Fosun introduced several latest products that are leading industry transformation. In the field of neurological disease treatment, especially for conditions like essential tremor and Parkinson's disease, patients have long faced challenges with unmet clinical needs. Traditional drug and surgical treatments often have limitations, but advancements in non-invasive treatment technologies have brought new hope to these patients. Fosun has actively responded to this unmet clinical need. At this year's CIIE, the new V2 model of the CNS (Central Nervous System) innovative treatment technology, the V2 model of "Exablate Neuro FUS system" made its debut in China, generating high expectations within the industry. This new model has already received CE certification in Europe and FDA approval in the United States and submitted a registration application to China's National Medical Products Administration in 2024. The V2 model's innovation lies in providing a non-invasive surgical solution for clinically drug-resistant essential tremor and tremor-dominant Parkinson's disease, while also being compatible with a broader range of MRI models, further enhancing the accessibility of this technology. Last year, Fosun, in partnership with Insightec, showcased the "Exablate Neuro" at CIIE, drawing much attention and continuous interest in collaboration. Leveraging the CIIE's "spillover effect", Fosun Pharma and Insightec established a joint venture, Fosun-Insightec, in February this year. The venture is focused on the marketing and developing clinical efforts of Exablate Neuro FUS system in improving the lives of patient living with essential tremor and Parkinson's disease, working to help them regain their quality life and wellbeing. Focusing on innovating to meet real customer needs is a core methodology for Fosun. Data shows that Fosun has made long-term investments in technological innovation, with an investment of RMB 3.5 billion in the first half of this year. Connecting Globally to Enhance Accessibility of Innovative Drugs, Benefiting more Patients Leveraging the CIIE's openness, Fosun also presented innovative products focused on solid tumors, hematological tumors, and immune-inflammatory conditions. Fosun's seven-year journey at CIIE has facilitated the introductions of global products and enabled the export of local innovations to benefit more patients worldwide. In 2017, Fosun introduced China's first CAR-T cell therapy product, Yi Kai Da (ejilunsai injection). Since then, by continuously participating in the CIIE, Fosun has enabled the public to gain an in-depth understanding of this advanced therapy. At this year's CIIE, Fosun highlighted Yi Kai Da's latest developments in the "accessibility and treatability" in lymphoma treatment. Yi Kai Da is now included in over 110 urban customized commercial health insurances and more than 80 commercial insurances, created a new path of payment mode for patients; and over 170 high-standard treatment centers across 28 regions in China providing treatments for over 900 lymphoma patients, achieving revolutionary innovative breakthroughs for cancer care. As a global company rooted in China, Fosun has an extensive industrial presence in over 35 countries and regions worldwide, with robust global R&D capabilities and impressive progress. This year, Fosun also showcased several innovative products, including the world's first and only dual-channel fixed-dose combination oral formulation, Akynzeo® oral (Netupitant and Palonosetron hydrochloride), which blocks both NK-1 and 5-HT3 receptors; the immunoglobulin Thymoglobulin® for improving transplant patient outcomes; the world's first oral targeted medication for psoriasis, Otezla® (apremilast tablets); a new third-generation COMT inhibitor Ongentys® (Opicapone) for managing symptom fluctuations in adult Parkinson's disease patients; and Parsabiv® (Etelcalcetide Hydrochloride Injection), the only peptide-based calcimimetic for treating secondary hyperparathyroidism in adult dialysis patients with chronic kidney disease. Guo Guangchang concluded, "Participating in CIIE has been a top priority for Fosun for seven consecutive years. We have witnessed CIIE become a crucial platform for global companies to share in China's development opportunities and deepened our global partnerships through this platform. We believe the CIIE stage will continue to expand, and Fosun's journey of innovation and globalization will grow broader."
SINGAPORE - Media OutReach Newswire - 7 November 2024 - Held at the Grand Hyatt Taipei on 13 September, the much-anticipated Asia Pacific Enterprise Awards (APEA) 2024 Taiwan recognized many leading companies and entrepreneurs for their success and excellent leadership. The APEA is Asia's premier awards recognition program promoting outstanding entrepreneurship, bringing together top entrepreneurs, and fostering networking between various industries. Alljack Technologies, Inc. was among the top enterprises who received recognition during the grand awards ceremony, winning two APEA trophies under the 'Inspirational Brand' and 'Master Entrepreneur' categories. Established in 2013, Alljack Technologies is a leading provider of precision metal and plastic components, specializing in the transition from traditional manufacturing to CNC machining. The company's expertise is sought after by industries demanding high-precision products, including aerospace, satellites, medical devices, optical modules, and drones. The company offers a versatile range of manufacturing capabilities, catering to both small-scale research and development projects and large-scale production needs. While primarily focused on the North American market, the company also has a strong presence in Israel, Germany, and Japan. Alljack Technologies aims to establish itself as a one-stop solution for CNC manufacturing, fostering mutual growth and prosperity with its clients and partners. The company is on the right track to achieve its goal as its core strength lies in its rigorous production processes and cost-effective operations, backed by international quality certifications such as AS9100, ISO9001, ISO13485, and ISO27001. The company also aims to be the preferred partner for aerospace, medical, and 3C industries, while prioritizing employee satisfaction. As a member of the Aerospace Industrial Development Association, Alljack Technologies is highly regarded by Taiwan's high-tech and precision CNC machining industries. Alljack Technologies CEO and Founder, Lai Wen Chang, has been recognized as a Master Entrepreneur for his exceptional business acumen. The award serves as a testament to his strong leadership skills and perseverance when faced with challenges. Lai Wen Chang was appointed Chairman of Alljack Technologies in 2021. The company had struggled with eight consecutive years of losses due to mismanagement. Under Lai Wen Chang's guidance, Alljack Technologies underwent a remarkable turnaround. Driven by the motto "Heaven rewards the diligent," Lai Wen Chang led the company through the challenges of the pandemic. Despite a severe manpower shortage, he personally stepped in to assist on the production line, ensuring timely customer deliveries. This proactive leadership helped the company secure large orders for medical equipment, contributing to significant growth and profitability. In just a few years, Lai Wen Chang transformed Alljack Technologies from a struggling company to a thriving success. His strategic leadership and unwavering dedication to his team have been instrumental in the company's turnaround. The APEA's Master Entrepreneur recognition is a well-deserved honor that celebrates Lai Wen Chang's extraordinary contributions to the field of entrepreneurship. Hashtag: #EnterpriseAsiaThe issuer is solely responsible for the content of this announcement.About Enterprise AsiaEnterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are an investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplift the economic status of people across Asia, and ensure a legacy of hope, innovation, and courage for future generations. Please visit www.enterpriseasia.org for more information. About Asia Pacific Enterprise AwardsLaunched in 2007, the Asia Pacific Enterprise Awards is the region's most prestigious award for outstanding entrepreneurship, continuous innovation, and sustainable leadership. The Award provides a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices, and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation-only networking powerhouse. The program has grown to encompass 16 countries/regions and markets all over Asia. For further information, please visit www.apea.asia.
Hsinchu, Taiwan, November 7, 2024 – ACE Biotek is at the forefront of smart hospital development in Taiwan, focusing on digital integration systems for ophthalmology, anesthesia, and electronic medical records. These advanced healthcare solutions have been successfully implemented at Shin Kong Wu Ho-Su Memorial Hospital and other leading healthcare institutions across Taiwan, receiving widespread acclaim. ACE Biotek has been invited to exhibit its solutions at the 2024 Healthcare Expo Taiwan from December 5 to December 8. We warmly invite industry professionals to visit our booth and experience the technology firsthand. Don't miss this opportunity to witness the future of healthcare! The EP100 Ophthalmology Recording System (EaglePark100) can connect with ophthalmic examination equipment, allowing patient data and examination results to be directly displayed on tablet devices, eliminating the need for thermal paper printing and achieving structured data management and a paperless workflow. It supports real-time data transfer among multiple roles, including attending physicians, assistant doctors, nurses, and examination rooms, enhancing clinical efficiency. The user-friendly interface also enables physicians to hand-draw diagnostic illustrations. The Spark Surgical Anesthesia System digitally integrates data processing for pre-, intra-, and post-operative care across nursing and anesthesia departments, supporting medication management and surgical protocols. It achieves a "real-time and comprehensive collection of physiological monitor and anesthesia machine data." Leveraging medical AI and big data analysis, the system can seamlessly connect with hospital HIS, surgical, and billing systems, significantly enhancing operational efficiency and accuracy by recording real-time anesthesia events and medical interventions. Exhibition Highlights: 🏥 Spark Surgical Anesthesia System 📝 EP100 Ophthalmology Recording System (EaglePark100) 💡 DS Data Integration System Exhibition Information: 🌟Location: TaiNEX Hall 1, Booth J118 @ Shin Kong Wu Ho-Su Memorial Hospital ACE Biotek is seeking collaboration with hospitals and international system integrators (SIs). We welcome healthcare institutions and SI partners from around the world to visit and discuss potential technical and business partnerships. 👉🏻 Booth Tour spots are limited and will be arranged based on availability, so please register early: https://docs.google.com/forms/d/e/1FAIpQLSci4DL2BZeePk-xAcF-wSOk6284zsjLEA7pzCdBC3InGQqfPA/viewform Contact: Jenny Lin (Marketing Assistant Manager) jenny_lin@acebiotek.com +886-3-5500909#3407/ +886-922168765 About ACE Biotek Established in 2000, ACE Group has grown for more than 20 years across wireless and healthcare industries. Originally, ACE Group formed ACE Solution as its first foray to focus on wireless communication, networking hardware, and customized system integration projects. Driven by President Steve’s vision to improve healthcare quality, he built the ACE Biotek building from the ground up and officially founded ACE Biotek in 2018. ACE Biotek integrates the past 20 years of industrial experience and knowledge to solve unmet clinical needs. In order to achieve the early diagnosis of diseases, we have developed smart medical solutions regarding imaging algorithms, cloud computing, artificial intelligence, and terahertz technology so far. Long term, ACE Biotek will expand globally to serve as a platform to cultivate talents and support tech companies to transform into Medtech. Contact ACE Biotek Advanced ACE Biotek Co., Ltd. Address: No. 66, Shengyi 2nd Rd., Zhubei City, Hsinchu County 302, Taiwan (Hsinchu Biomedical Science Park) Phone: +886-3-5500909 E-mail: service@acebiotek.com Website: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
台灣新竹，2024年11月07日 – 筑波醫電引領我國智慧醫院發展，專注於眼科與麻醉數位化整合系統及電子病歷系統的開發。相關智慧醫療方案已成功應用於新光醫院及多家國內具代表性的醫療機構，廣受好評。筑波醫電受邀參加2024年12月5日至12月8日台灣醫療科技展，將於現場展示方案，誠摯邀請各界人士蒞臨體驗與指教。 看得健100眼科數位紀錄系統 (EP100) 可串接眼科檢查儀器，讓病患資料與檢查數據直接顯示於平板裝置，無需列印感熱紙，實現數據結構化與無紙化管理。此外支持多角色協作如：主治醫師、協作醫師、護理師與檢查室之間的即時資料傳輸，提升看診效率。人性化界面可輔助醫師手繪診斷。 Spark手術麻醉系統則數位化整合護理部與麻醉部在手術前、中、後資料處理，並支援藥物管理與手術模式，實現「即時且完整收集生理監視器與麻醉機資料」。結合醫療AI大數據分析，可靈活對接醫院的HIS、手術系統及批價系統，提升作業效率與準確性，即時記錄麻醉事件與醫護處置。 展出亮點： 🏥 Spark手術麻醉系統 📝 EP100眼科數位紀錄系統 (看得健100) 💡 DS數據上傳整合系統 展覽資訊： 🌟地點：台北南港展覽館一館，攤位：J118 @新光醫院 尋找合作醫院、國際醫療系統整合商 (SI) 合作夥伴，誠邀國內外醫療院所、SI商蒞臨參觀。歡迎各界夥伴蒞臨，討論技術及商業合作 👉🏻 Booth Tour名額有限，將依實際狀況安排，請及早報名：https://docs.google.com/forms/d/e/1FAIpQLSci4DL2BZeePk-xAcF-wSOk6284zsjLEA7pzCdBC3InGQqfPA/viewform Contact: Jenny Lin (Marketing Assistant Manager) jenny_lin@acebiotek.com +886-3-5500909#3407/ +886-922168765 關於筑波醫電ACE Biotek 筑波醫電大樓是董事長許深福先生驅動內心的寄望及理念，依據建築設計師、施工團隊及同仁們很科學的作品。是筑波人多年來文化、創意技術的展現，是筑波全體同仁長久對生醫產業接軌國際平台的堅持。筑波科技集團以豐富的無線通訊軟硬體整合經驗、結合半導體晶片、醫學影像演算法、雲端技術、人工智慧、臨床醫師專業、法規驗證與專利技術綜效，著力於人們早期病變篩檢系統的精準醫療設備產品研發與生產。期望不但可以減少病患及家人的遺憾，並開拓台灣本土精密無創微創醫檢設備能量且推廣於國際，更建立台灣從3C到三醫(醫才、醫技、醫材)的產業鏈轉型平台與人才的培育之目標。 連絡筑波醫電 筑波醫電股份有限公司Advanced ACE Biotek Co., Ltd. 地址：30261新竹縣竹北市生醫二路66號 (新竹生醫園區) 電話: +886-3-5500909 E-mail: service@acebiotek.com 網站: https://www.acebiotek.com/ Facebook: https://www.facebook.com/Acebiotek/ LinkedIn: https://www.linkedin.com/company/30620922/admin/
The significant investment increases the production of CEUS microbubbles The imaging platform for ultrasound, the fruit of Bracco's research, assists doctors all over the world with more accurate diagnostic data, improving patients' quality of life and facilitating personalized treatment plans PLAN-LES-OUATES, Switzerland, Nov. 6, 2024 /PRNewswire/ -- Over 80 million euros have been invested to build Hexagon, a new manufacturing facility located next to the historical 1997 plant which will, when fully operational, triple the production and distribution of one of the leading products from Bracco's research. The new multi-functional building will supply the world with the innovative contrast agent for ultrasound based on microbubbles, which allows real-time diagnosis and offers greater versatility as well as sustainability. It is the latest milestone in the Bracco Group's long-standing story of success. Founded in Milan in 1927, today the company operates in 100 countries while maintaining its strong Italian roots, and counts 1.8 billion euros in turnover and over 3,800 employees. Fulvio Renoldi Bracco (Vice Chairman and CEO of Bracco Imaging) & Diana Bracco (President and CEO of Bracco Group) The ties with Switzerland go back a long way: first the Research Center, nearly 40 years ago, followed by the Plan-les-Ouates manufacturing site. "It all began with collaboration between our research department and the Swiss Battelle Institute, which allowed us to explore cutting-edge modalities in diagnostic imaging," recalls Diana Bracco, President and CEO of the Group. "As a result of this new major investment, we will be in a position to satisfy the high global demand for our products. For us, as a family company, it is both an achievement and a great source of pride to be able to compete on a global scale in such a technologically advanced sector. We have invested on average 12.5 million francs per year over the last decade in R&D at the Geneva Research Center," concluded Diana Bracco, "employing more than 45 scientists and researchers. Furthermore, it is precisely the proximity of the research and development department to production which is an essential factor in the success of Bracco Suisse." Contrast-Enhanced Ultrasound is a high-sensitivity, non-invasive diagnostic imaging modality free of radiation, capable of enhancing the visibility, and therefore the evaluation, of heart cavities, blood vessels and tissue vascularity. Microbubbles also have enormous potential in the field of precision medicine because they can serve as vectors of pharmaceuticals, activating the temporary opening of the vascular tissue barrier thereby optimizing the therapeutic effect, making it as targeted and effective as possible. "Bracco has always been at the forefront of scientific progress because innovation is in our DNA," stated Fulvio Renoldi Bracco, Vice Chairman and CEO of Bracco Imaging. "With this ambitious project, which enables us to triple and expand our production lines, Bracco aims to become the global leader in the CEUS sector. We see the potential of this modality as a complement to X-ray, magnetic resonance and PET/SPECT to help health systems deliver more efficient care to their patients. Our microbubble platform is a more convenient, cutting-edge medical technology that adds value to diagnostic imaging. We will continue to invest in this area in the near future, as it has already delivered excellent results internationally." Inauguration day for the new plant - a 4-story building characterized by contemporary design and constructed according to the most rigorous sustainability standards - began with a symbolic ribbon-cutting ceremony attended by, along with Diana Bracco and Fulvio Renoldi Bracco, Anne Lévy, Director of the FOPH – Federal Office of Public Health, Xavier Magnin, Mayor of Plan-les-Ouates, Monika Schmutz Kirgöz, Ambassador of Switzerland to Italy, Gian Lorenzo Cornado, Ambassador of Italy to Switzerland, Alexandre Epalle, Director General of Economic Development, Research, and Innovation for the Canton of Geneva and Simona Loizzo, member of the Italian Parliament. In their speeches, the ambassadors from the two countries highlighted the friendly relations between Italy and Switzerland, the value of the investment in the Canton of Geneva, and Bracco's role in one of the most advanced sectors of the Life Sciences and of prevention. In the afternoon, the scientific symposium "Bubble Power – Imaging & Beyond" was held at the Spark Auditorium to celebrate the event. Moderated by Fabio Tedoldi, Head of Global Research & Development at Bracco Imaging, the convention featured introductory remarks by Cristina Messa, Full Professor of Diagnostic Imaging and Radiotherapy at the University of Milano-Bicocca and former Italian Minister of University and Research, and speeches by Alberto Spinazzi, Senior Vice President, Chief Medical and Regulatory Officer, Thierry Bettinger, Geneva Research Center Director, and Vincent Letondal, Site Manager-Operations Director, Bracco Suisse SA, as well as numerous valuable contributions from international scientists, managers and specialists. Bracco is an international Group active in over 100 countries worldwide in the healthcare sector and a leader in diagnostic imaging. It has over 3,800 employees and annual total consolidated revenues of around 1,8 billion euros, 88% of which from international sales. In the Research and Development area, the company invests approximately 10% of reference turnover in the imaging diagnostics and medical devices sectors and has a portfolio comprising over 2,600 patents.
BEIJING, Nov. 6, 2024 /PRNewswire/ -- MEGAROBO, a leading provider of advanced productivity tools for life sciences, has recently unveiled the CellVue™ T2000 high-content cell imaging system. The new cell imaging system is more than a digital microscope, featuring a high-sensitivity CMOS imaging camera that seamlessly integrates automated multi-color fluorescence imaging with quantitative data analysis. The system enables in-depth exploration of the multi-dimensional characteristics of individual cells in biological samples, serving a wide range of applications, from basic research to drug discovery and preclinical trials. The technology provides scientists with rapid, high-resolution cell imaging and comprehensive, accurate data support. As the latest breakthrough in life science research tools, MEGAROBO's proprietary CellVue™ T2000 builds upon the strengths of traditional high-content imaging systems while achieving remarkable strides in imaging speed, configurability, and functional versatility. With unprecedented efficiency, the system meets the urgent need for high-throughput imaging in complex experimental scenarios, enhancing data stability, reliability, and experimental reproducibility. Furthermore, the solution offers extensive upgrade options for cytotoxicity studies, cell painting and 3D sample studies, ensuring optimal configurations that address the specific needs of different research teams. In addition, the CellVue™ T2000 has been fully incorporated into AutoBio™, the laboratory automation system developed by MEGAROBO. This integration enables a fully automated workflow from cell seeding, passaging and drug delivery to image detection and analysis. "Whether examining the fine structure of the cytoskeleton and nucleus or the spatial relationships between functional proteins, the system can deliver high-definition images and precise data," said Daniel Huang, Founder and CEO of MEGAROBO. "The capability allows researchers to gain deeper insights into cell biology phenomena and mechanisms. With the CellVue™ T2000 as a starting point, MEGAROBO will continue to facilitate technological innovation in the life sciences sector, inspiring deeper exploration into uncharted territories." With a global footprint spanning China, the U.S., Europe, and Southeast Asia, MEGAROBO has solidified its position as a leading force in intelligent automation and life sciences innovation worldwide. About MEGAROBO Founded in 2016, MEGAROBO is a science and technology company specializing in providing advanced production tools for life sciences, drug discovery, clinical diagnostics and applied chemistry industries. MEGAROBO has closed the Series C financing round, securing long-term support from key investors including WuXi AppTec, Bosch, Sino Biological, Goldman Sachs Asset Management, Asia Investment Capital, Jiyuan Capital, Sinovation Ventures, Joy Capital, MPCi and Pavilion Capital.
A12 藝術空間
Medical Equipment
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
